Vomizole 20mg tablets
Dexa Medica
Ingredients in every tablet
Pantoprazole | 20 mg |
Each package contains
Other details
Flavour | None |
W.H.O. classification
ATC Level 1 | A - Alimentary tract and metabolism |
ATC Level 2 | A02 - Drugs for Acid Related Disorders |
ATC Level 3 | A02B - Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord) |
Warnings
Pregnancy
Lactation
Alcohol
Machinery
Available in
![]() |
Indonesia |
Dosage information
18 TO 65 YEARS OLD
• Symptomatic gastroesophageal reflux disease (GERD) or nonerosive reflux disease (NERD):
The recommended oral dose is 20 mg per day. Symptom relieve is generally accomplished within 2-4 weeks and a 4 weeks treatment period is usually required for healing of associated esophagitis. If this is not sufficient, healing will normally be achieved within a further 4 weeks. When symptom relief has been achieved, recurring symptoms can be controlled using an on-demand regimen of 20 mg once daily when required. A switch to Continuous therapy may be considered in case satisfactory symptom control cannot be maintained with on-demand treatment.
• For long-term management of moderate and severe form of reflux esophagitis: For long-term management, a maintenance dose 20 mg per day is recommended, increasing to 40 mg per day if relapse occur. After healing of relapse the dosage can be reduced again to 20 mg pantoprazole.
Tablet should not be chewed or crushed and should be swallowed whole, 1 hour before a meal with some water.
65 YEARS OLD AND ABOVE
No dose adjustment is necessary in elderly patients or in patients with impaired renal function.
Tablet should not be chewed or crushed and should be swallowed whole, 1 hour before a meal with some water.
0 TO 18 YEARS OLD
To date there has been no experience with treatment in children.
Tablet should not be chewed or crushed and should be swallowed whole, 1 hour before a meal with some water.
LIVER IMPAIRMENT
A daily dose of 20 mg pantoprazole should not be exceeded in patients with severe liver impairment.
Patients who do not respond after 4 weeks should be investigated.
Indication
– Symptomatic gastroesophageal reflux disease (GERD) or nonerosive reflux disease (NERD).
– For long-term management of moderate and severe form of reflux esophagitis.